Monalizumab: inhibiting the novel immune checkpoint NKG2A
Abstract The implementation of immune checkpoint inhibitors to the oncology clinic signified a new era in cancer treatment. After the first indication of melanoma, an increasing list of additional cancer types are now treated with immune system targeting antibodies to PD-1, PD-L1 and CTLA-4, allevia...
Na minha lista:
| Principais autores: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2019-10-01
|
| coleção: | Journal for ImmunoTherapy of Cancer |
| Assuntos: | |
| Acesso em linha: | http://link.springer.com/article/10.1186/s40425-019-0761-3 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|